Pasar al contenido principal

INGENIERIA GENETICA DEL MUSCULO ESQUELETICO PARA EXPRESAR INSULINA Y/O GLUCOQUINASA PARA EL TRATAMIENTO DE LA DIABETIS MELLITUS

SAF2011-24698

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2011
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pancreatic transduction by helper-dependent adenoviral vectors via intraductal delivery

  • Morró Larrubia, Meritxell|||0000-0003-1725-9599
  • Teichenne, Joan|||0000-0002-3455-5923
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Kratzer, Ramona
  • Marletta, Serena
  • Maggioni, Luca
  • Mallol, Cristina|||0000-0002-2920-9612
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Kochanek, Stefan
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Ayuso, Eduard|||0000-0003-0811-2229
Pancreatic gene transfer could be useful to treat several diseases, such as diabetes mellitus, cystic fibrosis, chronic pancreatitis, or pancreatic cancer. Helper-dependent adenoviral vectors (HDAds) are promising tools for gene therapy because of their large cloning capacity, high levels of transgene expression, and long-term persistence in immunocompetent animals. Nevertheless, the ability of HDAds to transduce the pancreas in vivo has not been investigated yet. Here, we have generated HDAds carrying pancreas-specific expression cassettes, that is, driven either by the elastase or insulin promoter, using a novel and convenient plasmid family and homologous recombination in bacteria. These HDAds were delivered to the pancreas of immunocompetent mice via intrapancreatic duct injection. HDAds, encoding a CMV-GFP reporter cassette, were able to transduce acinar and islet cells, but transgene expression was lost 15 days postinjection in correlation with severe lymphocytic infiltration. When HDAds encoding GFP under the control of the specific elastase promoter were used, expression was detected in acinar cells, but similarly, the expression almost disappeared 30 days postinjection and lymphocytic infiltration was also observed. In contrast, long-term transgene expression (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Insulin-like growth factor I (IGF-I)-induced chronic gliosis and retinal stress lead to neurodegeneration in a mouse model of retinopathy

  • Villacampa, Pilar|||0000-0002-2860-7475
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Motas, Sandra|||0000-0003-2748-5952
  • Ramírez, Laura
  • Garcia, Miquel|||0000-0002-1602-4993
  • de la Villa, Pedro|||0000-0001-9856-6616
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
Insulin-like growth factor I (IGF-I) exerts multiple effects on different retinal cell types in both physiological and pathological conditions. Despite the growth factor's extensively described neuroprotective actions, transgenic mice with increased intraocular levels of IGF-I showed progressive impairment of electroretinographic amplitudes up to complete loss of response, with loss of photoreceptors and bipolar, ganglion, and amacrine neurons. Neurodegeneration was preceded by the overexpression of genes related to retinal stress, acute-phase response, and gliosis, suggesting that IGF-I altered normal retinal homeostasis. Indeed, gliosis and microgliosis were present from an early age in transgenic mice, before other alterations occurred, and were accompanied by signs of oxidative stress and impaired glutamate recycling. Older mice also showed overproduction of pro-inflammatory cytokines. Our results suggest that, when chronically increased, intraocular IGF-I is responsible for the induction of deleterious cellular processes that can lead to neurodegeneration, and they highlight the importance that this growth factor may have in the pathogenesis of conditions such as ischemic or diabetic retinopathy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Insulin-like growth factor 2 overexpression induces β-Cell dysfunction and increases beta-cell susceptibility to damage

  • Casellas Comallonga, Alba|||0000-0003-0203-4733
  • Mallol, Cristina|||0000-0002-2920-9612
  • Salavert Larrosa, Ariana
  • Jimenez, Veronica|||0000-0001-9145-9877
  • García Martínez, Miguel
  • Agudo, Judith|||0000-0002-3576-3169
  • Mercè Obach, Mercè
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Vilà Prats, Laia
  • Molas, Maria
  • Lage, Ricardo
  • Morró Larrubia, Meritxell|||0000-0003-1725-9599
  • Casaña Lorente, Estefania|||0000-0002-1353-5018
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
The human insulin-like growth factor 2 (IGF2) and insulin genes are located within the same genomic region. Although human genomic studies have demonstrated associations between diabetes and the insulin/IGF2 locus or the IGF2 mRNA-binding protein 2 (IGF2BP2), the role of IGF2 in diabetes pathogenesis is not fully understood. We previously described that transgenic mice overexpressing IGF2 specifically in β-cells (Tg-IGF2) develop a pre-diabetic state. Here, we characterized the effects of IGF2 on β-cell functionality. Overexpression of IGF2 led to β-cell dedifferentiation and endoplasmic reticulum stress causing islet dysfunction in vivo. Both adenovirus-mediated overexpression of IGF2 and treatment of adult wild-type islets with recombinant IGF2 in vitro further confirmed the direct implication of IGF2 on β-cell dysfunction. Treatment of Tg-IGF2 mice with subdiabetogenic doses of streptozotocin or crossing these mice with a transgenic model of islet lymphocytic infiltration promoted the development of overt diabetes, suggesting that IGF2 makes islets more susceptible to β-cell damage and immune attack. These results indicate that increased local levels of IGF2 in pancreatic islets may predispose to the onset of diabetes. This study unravels an unprecedented role of IGF2 on β-cells function.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Toward a gene therapy for neurological and somatic MPSIIIA

  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Mucopolysaccharidosis Type IIIA (MPSIIIA) represents an unmet medical need. MPSIIIA shares with many other lysosomal storage disorders (LSD) the characteristic of being a severe neurodegenerative disease accompanied by mild somatic involvement. Thus, the main target organ for the development of new treatments is the central nervous system (CNS), but overall clinical efficacy would be greatly enhanced by simultaneous correction of peripheral disease. We have recently developed a novel treatment for MPSIIIA based on the delivery to the cerebrospinal fluid of serotype 9 adeno-associated virus (AAV9)-derived vectors. This gene therapy strategy corrected both CNS and somatic pathology in animal models through widespread transduction of CNS, peripheral nervous system (PNS), and liver. The work set the grounds for the clinical translation of the approach to treat MPSIIIA in humans. Here we discuss some important considerations that further support the applicability of this treatment to MPSIIIA and other LSD with CNS and somatic involvement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

New insights into adipose tissue VEGF-A actions in the control of obesity and insulin resistance

  • Elias Puigdomenech, Ivet|||0000-0002-1304-9597
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Vascular endothelial growth factor A (VEGF-A) is classically viewed as a key factor in angiogenesis and tissue remodeling. However, recent evidence suggests a potential role of this growth factor in the control of energy metabolism and adipose tissue function. In this regard, we and others have described the effects of the up and downregulation of VEGF-A in adipose tissue on the control of energy homeostasis. VEGF-A overexpression protects against diet-induced obesity and insulin resistance. The observation that VEGF-A overexpression leads to an increase in brown adipose tissue (BAT) thermogenesis and also promotes a "BAT-like" phenotype in white adipose tissue depots is of particular relevance for the understanding of the mechanisms underlying obesity development. In addition, VEGF-A may not only have pro-inflammatory but also anti-inflammatory properties, with a chemotactic activity specific for M2 anti-inflammatory macrophages. This new scientific evidence highlights the importance that VEGF-A actions on metabolism could have on the design of new treatments for obesity, insulin resistance and obesity-related disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In Vivo Adeno-Associated Viral Vector-Mediated Genetic Engineering of White and Brown Adipose Tissue in Adult Mice

  • Jimenez, Veronica|||0000-0001-9145-9877
  • Muñoz-Martínez, S|||0000-0003-0663-0575
  • Casaña Lorente, Estefania|||0000-0002-1353-5018
  • Mallol, Cristina|||0000-0002-2920-9612
  • Elias Puigdomenech, Ivet|||0000-0002-1304-9597
  • Jambrina Pallarés, Claudia
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Ferre, Tura|||0000-0001-9713-0829
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Adipose tissue is pivotal in the regulation of energy homeostasis through the balance of energy storage and expenditure and as an endocrine organ. An inadequate mass and/or alterations in the metabolic and endocrine functions of adipose tissue underlie the development of obesity, insulin resistance, and type 2 diabetes. To fully understand the metabolic and molecular mechanism(s) involved in adipose dysfunction, in vivo genetic modification of adipocytes holds great potential. Here, we demonstrate that adeno-associated viral (AAV) vectors, especially serotypes 8 and 9, mediated efficient transduction of white (WAT) and brown adipose tissue (BAT) in adult lean and obese diabetic mice. The use of short versions of the adipocyte protein 2 or uncoupling protein-1 promoters or micro-RNA target sequences enabled highly specific, long-term AAV-mediated transgene expression in white or brown adipocytes. As proof of concept, delivery of AAV vectors encoding for hexokinase or vascular endothelial growth factor to WAT or BAT resulted in increased glucose uptake or increased vessel density in targeted depots. This method of gene transfer also enabled the secretion of stable high levels of the alkaline phosphatase marker protein into the bloodstream by transduced WAT. Therefore, AAV-mediated genetic engineering of adipose tissue represents a useful tool for the study of adipose pathophysiology and, likely, for the future development of new therapeutic strategies for obesity and diabetes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HMGA1 overexpression in adipose tissue impairs adipogenesis and prevents diet-induced obesity and insulin resistance

  • Arce Cerezo, Altamira
  • Garcia, Miquel|||0000-0002-1602-4993
  • Rodríguez-Nuevo, Aida|||0000-0002-4233-8398
  • Crosa-Bonell, Mireia
  • Enguix, Natàlia|||0000-0002-7873-902X
  • Peró, Albert
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Roca Lecha, Carles|||0000-0002-3744-3089
  • Ramos Gonzalez, David|||0000-0002-8574-218X
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Elias Puigdomenech, Ivet|||0000-0002-1304-9597
  • Ferre, Tura|||0000-0001-9713-0829
  • Pujol i Altarriba, Anna|||0000-0002-3484-598X
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Villena, Josep A.|||0000-0002-2200-2985
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Riu, Efrén|||0000-0002-2574-3578
High-Mobility-Group-A1 (HMGA1) proteins are non-histone proteins that regulate chromatin structure and gene expression during embryogenesis, tumourigenesis and immune responses. In vitro studies suggest that HMGA1 proteins may be required to regulate adipogenesis. To examine the role of HMGA1 in vivo, we generated transgenic mice overexpressing HMGA1 in adipose tissues. HMGA1 transgenic mice showed a marked reduction in white and brown adipose tissue mass that was associated with downregulation of genes involved in adipogenesis and concomitant upregulation of preadipocyte markers. Reduced adipogenesis and decreased fat mass were not associated with altered glucose homeostasis since HMGA1 transgenic mice fed a regular-chow diet exhibited normal glucose tolerance and insulin sensitivity. However, when fed a high-fat diet, overexpression of HMGA1 resulted in decreased body-weight gain, reduced fat mass, but improved insulin sensitivity and glucose tolerance. Although HMGA1 transgenic mice exhibited impaired glucose uptake in adipose tissue due to impaired adipogenesis, the increased glucose uptake observed in skeletal muscle may account for the improved glucose homeostasis. Our results indicate that HMGA1 plays an important function in the regulation of white and brown adipogenesis in vivo and suggests that impaired adipocyte differentiation and decreased fat mass is not always associated with impaired whole-body glucose homeostasis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biochemical, histological and functional correction of mucopolysaccharidosis Type IIIB by intra-cerebrospinal fluid gene therapy

  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Garcia, Miquel|||0000-0002-1602-4993
  • Marcó, Sara|||0000-0003-3502-5198
  • Motas, Sandra|||0000-0003-2748-5952
  • Villacampa, Pilar|||0000-0002-2860-7475
  • Maggioni, Luca
  • León, Xavier|||0000-0002-8393-2721
  • Molas Laplana, Maria|||0000-0002-3215-515X
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Leborgne, Christian
  • Moll, Xavier|||0000-0002-2992-9361
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Mingozzi, Federico
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Añor Torres, Sònia|||0000-0002-1099-7698
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Gene therapy is an attractive tool for the treatment of monogenic disorders, in particular for lysosomal storage diseases (LSD) caused by deficiencies in secretable lysosomal enzymes in which neither full restoration of normal enzymatic activity nor transduction of all affected cells are necessary. However, some LSD such as Mucopolysaccharidosis Type IIIB (MPSIIIB) are challenging because the disease's main target organ is the brain and enzymes do not efficiently cross the blood-brain barrier even if present at very high concentration in circulation. To overcome these limitations,we delivered AAV9 vectors encoding for α-N-acetylglucosaminidase (NAGLU) to the Cerebrospinal Fluid (CSF) of MPSIIIB mice with the disease already detectable at biochemical, histological and functional level. Restoration of enzymatic activity in Central Nervous System (CNS) resulted in normalization of glycosaminoglycan content and lysosomal physiology, resolved neuroinflammation and restored the pattern of gene expression in brain similar to that of healthy animals. Additionally, transduction of the liver due to passage of vectors to the circulation led to whole-body disease correction. Treated animals also showed reversal of behavioural deficits and extended lifespan. Importantly, when the levels of enzymatic activity were monitored in the CSF of dogs following administration of canine NAGLU-coding vectors to animals that were either naïve or had pre-existing immunity against AAV9, similar levels of activity were achieved, suggesting that CNS efficacy would not be compromised in patients seropositive for AAV9. Our studies provide a strong rationale for the clinical development of this novel therapeutic approach as the treatment for MPSIIIB.